




Searching News Database: NeurogesX
HSMN NewsFeed - 31 Oct 2011
NeurogesX Appoints Dr. Stephen J. Peroutka as Executive Vice President and Chief Medical Officer
NeurogesX Appoints Dr. Stephen J. Peroutka as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 19 Nov 2010
NeurogesX Receives Qutenza(R)-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
NeurogesX Receives Qutenza(R)-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
HSMN NewsFeed - 23 Sep 2010
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
HSMN NewsFeed - 5 Apr 2010
Qutenza(R) (capsaicin) 8% Patch for Treatment of Post-Shingles Pain Now Available
Qutenza(R) (capsaicin) 8% Patch for Treatment of Post-Shingles Pain Now Available
HSMN NewsFeed - 24 Nov 2009
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
HSMN NewsFeed - 17 Jul 2009
NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
HSMN NewsFeed - 2 Jun 2009
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
HSMN NewsFeed - 19 Mar 2009
NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
HSMN NewsFeed - 22 Oct 2008
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
HSMN NewsFeed - 27 Sep 2007
NeurogesX' NGX-4010 MAA Filed and Accepted for Review by EMEA for Treatment of Peripheral Neuropathic Pain
NeurogesX' NGX-4010 MAA Filed and Accepted for Review by EMEA for Treatment of Peripheral Neuropathic Pain
HSMN NewsFeed - 4 Sep 2007
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
HSMN NewsFeed - 11 Jun 2007
NeurogesX Completes Enrollment in Phase 3 Clinical Trial for Postherpetic Neuralgia
NeurogesX Completes Enrollment in Phase 3 Clinical Trial for Postherpetic Neuralgia
HSMN NewsFeed - 18 Oct 2006
NeurogesX Phase 3 Study in Post-Herpetic Neuralgia Meets Primary Endpoint
NeurogesX Phase 3 Study in Post-Herpetic Neuralgia Meets Primary Endpoint
HSMN NewsFeed - 13 Jun 2006
NeurogesX Completes Enrollment in Pivotal Phase 3 Postherpetic Neuralgia Trial
NeurogesX Completes Enrollment in Pivotal Phase 3 Postherpetic Neuralgia Trial
Additional items found! 19

Members Archive contains
19 additional stories matching:
NeurogesX
(Password required)
NeurogesX
(Password required)